Venkatakrishnan K - Search Results

1

Oncology Combination Drug Development Strategies for Project Optimus.

Yap TA, Bullock J, Chong S, Doyle MK, Hussain A, Kline J, Manon A, Venkatakrishnan K, Upreti VV. Yap TA, et al. Among authors: venkatakrishnan k. Clin Cancer Res. 2024 Dec 2;30(23):5237-5241. doi: 10.1158/1078-0432.CCR-24-1836. Clin Cancer Res. 2024. PMID: 39365679 Review.

2

Biotransformation of an alpha4beta2 nicotinic acetylcholine receptor partial agonist in sprague-dawley rats and the dispositional characterization of its N-carbamoyl glucuronide metabolite.

Shaffer CL, Ryder TF, Venkatakrishnan K, Henne IK, O'Connell TN. Shaffer CL, et al. Among authors: venkatakrishnan k. Drug Metab Dispos. 2009 Jul;37(7):1480-9. doi: 10.1124/dmd.109.027037. Epub 2009 Apr 1. Drug Metab Dispos. 2009. PMID: 19339375

3

CYP3A5 polymorphism and alprazolam pharmacokinetics/pharmacodynamics.

Venkatakrishnan K, Gibbs MA. Venkatakrishnan K, et al. Clin Pharmacol Ther. 2006 Dec;80(6):719-20; author reply 720. doi: 10.1016/j.clpt.2006.09.013. Clin Pharmacol Ther. 2006. PMID: 17178274 No abstract available.

4

Mechanism of cytochrome P450-3A inhibition by ketoconazole.

Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL. Greenblatt DJ, et al. Among authors: venkatakrishnan k. J Pharm Pharmacol. 2011 Feb;63(2):214-21. doi: 10.1111/j.2042-7158.2010.01202.x. J Pharm Pharmacol. 2011. PMID: 21235585

5

Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.

Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ. Venkatakrishnan K, et al. J Pharm Pharmacol. 1998 Mar;50(3):265-74. doi: 10.1111/j.2042-7158.1998.tb06859.x. J Pharm Pharmacol. 1998. PMID: 9600717

6

Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.

Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. Venkatakrishnan K, et al. Xenobiotica. 2007 Oct-Nov;37(10-11):1225-56. doi: 10.1080/00498250701670945. Xenobiotica. 2007. PMID: 17968744 Review.

7

Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humans.

Shaffer CL, Gunduz M, Vaz AD, Venkatakrishnan K, Burstein AH. Shaffer CL, et al. Among authors: venkatakrishnan k. Drug Metab Dispos. 2008 Apr;36(4):655-62. doi: 10.1124/dmd.107.019760. Epub 2008 Jan 7. Drug Metab Dispos. 2008. PMID: 18180269

8

Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.

Venkatakrishnan K, Culm KE, Ehrenberg BL, Harmatz JS, Corbett KE, Fleishaker JC, Greenblatt DJ. Venkatakrishnan K, et al. J Clin Pharmacol. 2005 May;45(5):529-37. doi: 10.1177/0091270004269105. J Clin Pharmacol. 2005. PMID: 15831776 Clinical Trial.

9

Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.

Venkatakrishnan K, Obach RS. Venkatakrishnan K, et al. Curr Drug Metab. 2007 Jun;8(5):449-62. doi: 10.2174/138920007780866861. Curr Drug Metab. 2007. PMID: 17584016

10

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.

Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. Obach RS, et al. Among authors: venkatakrishnan k. J Pharmacol Exp Ther. 2006 Jan;316(1):336-48. doi: 10.1124/jpet.105.093229. Epub 2005 Sep 28. J Pharmacol Exp Ther. 2006. PMID: 16192315

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters